One Capital Management LLC Makes New Investment in GeneDx Holdings Corp. $WGS

One Capital Management LLC bought a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 12,053 shares of the company’s stock, valued at approximately $1,568,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jones Financial Companies Lllp lifted its holdings in GeneDx by 664.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after buying an additional 186 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in GeneDx during the 4th quarter worth about $35,000. Quarry LP lifted its holdings in GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after buying an additional 209 shares during the period. Gordian Capital Singapore Pte Ltd acquired a new position in GeneDx during the 3rd quarter worth about $65,000. Finally, AlphaQuest LLC lifted its holdings in GeneDx by 70.8% during the 3rd quarter. AlphaQuest LLC now owns 1,303 shares of the company’s stock worth $140,000 after buying an additional 540 shares during the period. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx Stock Down 0.2%

WGS stock opened at $53.02 on Thursday. The stock’s 50 day simple moving average is $55.99 and its 200 day simple moving average is $93.70. GeneDx Holdings Corp. has a fifty-two week low of $32.21 and a fifty-two week high of $170.87. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The company has a market cap of $1.57 billion, a P/E ratio of -19.78 and a beta of 1.96.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The company had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same period in the prior year, the firm posted ($0.23) earnings per share. On average, research analysts expect that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Analyst Ratings Changes

WGS has been the topic of a number of recent analyst reports. Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 24th. Wells Fargo & Company reissued an “overweight” rating and issued a $75.00 price objective (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Piper Sandler reissued an “overweight” rating and issued a $130.00 price objective (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Weiss Ratings downgraded GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. Finally, Jefferies Financial Group set a $150.00 price objective on GeneDx in a research note on Monday, February 23rd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and a consensus price target of $96.43.

Insiders Place Their Bets

In related news, Director Keith A. Meister acquired 46,273 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was purchased at an average cost of $38.91 per share, with a total value of $1,800,482.43. Following the acquisition, the director owned 4,784,570 shares of the company’s stock, valued at approximately $186,167,618.70. This trade represents a 0.98% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Kevin Feeley sold 392 shares of the business’s stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total value of $25,554.48. Following the sale, the chief financial officer directly owned 34,942 shares of the company’s stock, valued at $2,277,868.98. This represents a 1.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders purchased 2,056,420 shares of company stock valued at $82,035,340 and sold 72,382 shares valued at $4,889,473. Corporate insiders own 29.60% of the company’s stock.

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.